Published in Medical Device Law Weekly, September 23rd, 2007
"In addition to knowing the hormone receptor status (estrogen and progesterone), human epidermal receptor 2 (HER2) should be evaluated. The measurement of this parameter is essential to optimizing the systemic management," wrote N.J. Robert and colleagues.
The researchers concluded: "This article reviews the biology of HER2, testing for HER2, clinical studies evaluating HER2-based therapies, side effects (specifically cardiotoxicity), and strategies for HER2-based...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.